Categories
Change Password!
Reset Password!
In patients with small body size, H. pylori eradication found to be
successful with Vonoprazan-amoxicillin dual therapy, indicating therapy
adjustment as per body size.
In a recent study published
in Helicobacter
journal, comprising of 163
patients with Helicobacter pylori infection, the treatment success of vonoprazan and amoxicillin (VA)
dual therapy was associated with the small physique of patients.
This
study by Hiroyuki Eto et al.
investigated upon the clinical aspects
linked with Helicobacter pylori eradication rate with VA-dual therapy.
The patients having Helicobacter pylori on VA-dual (Vonoprazan 20 mg and Amoxicillin 750 mg both two
times a day for 7 days) therapy were recruited. The clinical aspects under
consideration were:
age,
gender, height, weight, body mass index (BMI), body surface area (BSA), earlier
records of initial gastric carcinoma and ulcer, co-morbidity of cirrhosis, smoking and alcohol intake,
frequent use of PPIs, and simultaneous use of medicines that are substrates of
cytochrome P450 (CYP) 3A4. The link between post-eradication adverse events and clinical
factors was
assessed.
The effectiveness of H. pylori eradication rate was
linked with a lesser BSA (90.8% rate in patients with BSA less than 1.723
versus 79.6% rate in those with BSA greater than equal to 1.723). Frequency of
adverse events was greater in women (40.0%) as compared to men (19.4%).
Considering the body size of the patients
can help to find the effectiveness of VA therapy in cases of Helicobacter pylori.
Helicobacter
Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy
Hiroyuki Eto et al.
Comments (0)